Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival

被引:57
作者
Giaginis, Constantinos [1 ,2 ]
Tsoukalas, Nikolaos [3 ]
Bournakis, Evangelos [3 ]
Alexandrou, Paraskevi [1 ]
Kavantzas, Nikolaos [1 ]
Patsouris, Efstratios [1 ]
Theocharis, Stamatios [1 ]
机构
[1] Univ Athens, Sch Med, Dept Pathol 1, 75 M Asias Str, GR-11527 Athens, Greece
[2] Univ Aegean, Sch Environm, Dept Food Sci & Nutr, Lemnos, Greece
[3] 401 Gen Mil Hosp, Dept Med Oncol, Athens, Greece
来源
BMC CLINICAL PATHOLOGY | 2014年 / 14卷
关键词
Ephrin receptors; Non-small cell lung carcinoma; Clinicopathological parameters; Prognosis; Immunohistochemistry;
D O I
10.1186/1472-6890-14-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Ephrin (Eph) receptors are frequently overexpressed in a wide variety of human malignant tumors, being associated with tumor growth, invasion, metastasis and angiogenesis. The present study aimed to evaluate the clinical significance of EphA1, A4, A5 and A7 protein expression in non-small cell lung carcinoma (NSCLC). Methods: EphA1, A4, A5 and A7 protein expression was assessed immunohistochemically in tissue microarrays of 88 surgically resected NSCLC and was analyzed in relation with clinicopathological characteristics and patients' survival. Results: Elevated EphA4 expression was significantly associated with low histopathological stage and presence of inflammation (p = 0.047 and p = 0.026, respectively). Elevated EphA7 expression was significantly associated with older patients' age, presence of fibrosis and smaller tumor size (p = 0.036, p = 0.029 and p = 0.018, respectively). EphA1, A5 and A7 expression were positively associated with tumor proliferative capacity (p = 0.047, p = 0.002 and p = 0.046, respectively). Elevated EphA4, A5 and A7 expression were identified as predictors of favourable patients' survival at both univariate (Log-rank test, 0 = 0.019, p = 0.006 and p = 0.012, respectively) and multivariate levels (Cox-regression analysis, p = 0.029, p = 0.068 and p = 0.044, respectively). Conclusions: The present study supported evidence that Ephs may be involved in lung cancer progression, reinforcing their utility as clinical biomarkers for patients' management and prognosis, as also as potential targets for future therapeutic interventions.
引用
收藏
页数:12
相关论文
共 42 条
  • [1] Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder
    Abraham, S
    Knapp, DW
    Cheng, L
    Snyder, PW
    Mittal, SK
    Bangari, DS
    Kinch, M
    Wu, L
    Dhariwal, J
    Mohammed, SI
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (02) : 353 - 360
  • [2] Epidemiology of lung cancer: Looking to the future
    Alberg, AJ
    Brock, MV
    Samet, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) : 3175 - 3185
  • [3] Brandley-Sieders DM, 2007, ANGIOGENESIS, V7, P17
  • [4] Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer
    Brannan, Jennifer M.
    Dong, Wenli
    Prudkin, Ludmila
    Behrens, Carmen
    Lotan, Reuben
    Bekele, B. Nebiyou
    Wistuba, Ignacio
    Johnson, Faye M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (13) : 4423 - 4430
  • [5] Clinical relevance of Ephs and ephrins in cancer: Lessons from breast, colorectal, and lung cancer profiling
    Brantley-Sieders, Dana M.
    [J]. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2012, 23 (01) : 102 - 108
  • [6] Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome
    Brantley-Sieders, Dana M.
    Jiang, Aixiang
    Sarma, Krishna
    Badu-Nkansah, Akosua
    Walter, Debra L.
    Shyr, Yu
    Chen, Jin
    [J]. PLOS ONE, 2011, 6 (09):
  • [7] Castano J, 2008, HISTOL HISTOPATHOL, V23, P1011, DOI 10.14670/HH-23.1011
  • [8] The ephrins and Eph receptors in angiogenesis
    Cheng, N
    Brantley, DM
    Chen, J
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (01) : 75 - 85
  • [9] Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    D'Addario, G.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 68 - 70
  • [10] Somatic mutations affect key pathways in lung adenocarcinoma
    Ding, Li
    Getz, Gad
    Wheeler, David A.
    Mardis, Elaine R.
    McLellan, Michael D.
    Cibulskis, Kristian
    Sougnez, Carrie
    Greulich, Heidi
    Muzny, Donna M.
    Morgan, Margaret B.
    Fulton, Lucinda
    Fulton, Robert S.
    Zhang, Qunyuan
    Wendl, Michael C.
    Lawrence, Michael S.
    Larson, David E.
    Chen, Ken
    Dooling, David J.
    Sabo, Aniko
    Hawes, Alicia C.
    Shen, Hua
    Jhangiani, Shalini N.
    Lewis, Lora R.
    Hall, Otis
    Zhu, Yiming
    Mathew, Tittu
    Ren, Yanru
    Yao, Jiqiang
    Scherer, Steven E.
    Clerc, Kerstin
    Metcalf, Ginger A.
    Ng, Brian
    Milosavljevic, Aleksandar
    Gonzalez-Garay, Manuel L.
    Osborne, John R.
    Meyer, Rick
    Shi, Xiaoqi
    Tang, Yuzhu
    Koboldt, Daniel C.
    Lin, Ling
    Abbott, Rachel
    Miner, Tracie L.
    Pohl, Craig
    Fewell, Ginger
    Haipek, Carrie
    Schmidt, Heather
    Dunford-Shore, Brian H.
    Kraja, Aldi
    Crosby, Seth D.
    Sawyer, Christopher S.
    [J]. NATURE, 2008, 455 (7216) : 1069 - 1075